These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 27689066)
1. Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Roberts MJ; Richards RS; Chow CW; Doi SA; Schirra HJ; Buck M; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA Prostate Int; 2016 Sep; 4(3):97-102. PubMed ID: 27689066 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828 [TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
4. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
5. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000 [TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079 [TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239 [TBL] [Abstract][Full Text] [Related]
8. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer. Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974 [TBL] [Abstract][Full Text] [Related]
10. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565 [TBL] [Abstract][Full Text] [Related]
11. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Wang R; Chinnaiyan AM; Dunn RL; Wojno KJ; Wei JT Cancer; 2009 Sep; 115(17):3879-86. PubMed ID: 19517474 [TBL] [Abstract][Full Text] [Related]
12. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer. Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666 [TBL] [Abstract][Full Text] [Related]
13. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851 [TBL] [Abstract][Full Text] [Related]
14. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580 [TBL] [Abstract][Full Text] [Related]
16. [The value of PHI/PCA3 in the early diagnosis of prostate cancer]. Tan SJ; Xu LW; Xu Z; Wu JP; Liang K; Jia RP Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(2):100-3. PubMed ID: 26792690 [TBL] [Abstract][Full Text] [Related]
17. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901 [TBL] [Abstract][Full Text] [Related]
18. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540 [TBL] [Abstract][Full Text] [Related]
19. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects. Schmid M; Hansen J; Chun FK Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372 [TBL] [Abstract][Full Text] [Related]
20. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]